Targeting aging with urolithin A in humans: A systematic review

Ajla Hodzic Kuerec; Xuan K. Lim; Anderson LY Khoo; Elena Sandalova; Lihuan Guan; Lei Feng; Andrea B. Maier

doi:10.1016/j.arr.2024.102406

Targeting aging with urolithin A in humans: A systematic review

Ajla Hodzic Kuerec, Xuan K. Lim, Anderson LY Khoo, Elena Sandalova, Lihuan Guan, Lei Feng, Andrea B. Maier^*

^*Corresponding author for this work

Research output: Contribution to Journal › Review article › Academic › peer-review

Abstract

Urolithin A (UA) is a gut metabolite derived from ellagic acid. This systematic review assesses the potential geroprotective effect of UA in humans. In five studies including 250 healthy individuals, UA (10–1000 mg/day) for a duration ranging from 28 days to 4 months, showed a dose-dependent anti-inflammatory effect and upregulated some mitochondrial genes, markers of autophagy, and fatty acid oxidation. It did not affect mitochondrial maximal adenosine triphosphate production, biogenesis, dynamics, or gut microbiota composition. UA increased muscle strength and endurance, however, had no effect on anthropometrics, cardiovascular outcomes, and physical function. Unrelated adverse events were mild or moderate. Further research across more physiological systems and longer intervention periods is required.

Original language	English
Article number	102406
Pages (from-to)	1-8
Number of pages	8
Journal	Ageing Research Reviews
Volume	100
Early online date	11 Jul 2024
DOIs	https://doi.org/10.1016/j.arr.2024.102406
Publication status	Published - Sept 2024

Bibliographical note

Publisher Copyright:
© 2024 The Authors

Funding

This article has been supported by the Lien Foundation.

Funders	Funder number
Lien Foundation

Keywords

Geroprotectors
Healthy aging
Longevity
Urolithin A

Access to Document

10.1016/j.arr.2024.102406

Persistent URL (handle)

Copy link address

Cite this

@article{20023dd6fc2d4ddb8bc022830a9bf7f8,

title = "Targeting aging with urolithin A in humans: A systematic review",

abstract = "Urolithin A (UA) is a gut metabolite derived from ellagic acid. This systematic review assesses the potential geroprotective effect of UA in humans. In five studies including 250 healthy individuals, UA (10–1000 mg/day) for a duration ranging from 28 days to 4 months, showed a dose-dependent anti-inflammatory effect and upregulated some mitochondrial genes, markers of autophagy, and fatty acid oxidation. It did not affect mitochondrial maximal adenosine triphosphate production, biogenesis, dynamics, or gut microbiota composition. UA increased muscle strength and endurance, however, had no effect on anthropometrics, cardiovascular outcomes, and physical function. Unrelated adverse events were mild or moderate. Further research across more physiological systems and longer intervention periods is required.",

keywords = "Geroprotectors, Healthy aging, Longevity, Urolithin A",

author = "Kuerec, {Ajla Hodzic} and Lim, {Xuan K.} and Khoo, {Anderson LY} and Elena Sandalova and Lihuan Guan and Lei Feng and Maier, {Andrea B.}",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors",

year = "2024",

month = sep,

doi = "10.1016/j.arr.2024.102406",

language = "English",

volume = "100",

pages = "1--8",

journal = "Ageing Research Reviews",

issn = "1568-1637",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Targeting aging with urolithin A in humans

T2 - A systematic review

AU - Kuerec, Ajla Hodzic

AU - Lim, Xuan K.

AU - Khoo, Anderson LY

AU - Sandalova, Elena

AU - Guan, Lihuan

AU - Feng, Lei

AU - Maier, Andrea B.

PY - 2024/9

Y1 - 2024/9

N2 - Urolithin A (UA) is a gut metabolite derived from ellagic acid. This systematic review assesses the potential geroprotective effect of UA in humans. In five studies including 250 healthy individuals, UA (10–1000 mg/day) for a duration ranging from 28 days to 4 months, showed a dose-dependent anti-inflammatory effect and upregulated some mitochondrial genes, markers of autophagy, and fatty acid oxidation. It did not affect mitochondrial maximal adenosine triphosphate production, biogenesis, dynamics, or gut microbiota composition. UA increased muscle strength and endurance, however, had no effect on anthropometrics, cardiovascular outcomes, and physical function. Unrelated adverse events were mild or moderate. Further research across more physiological systems and longer intervention periods is required.

AB - Urolithin A (UA) is a gut metabolite derived from ellagic acid. This systematic review assesses the potential geroprotective effect of UA in humans. In five studies including 250 healthy individuals, UA (10–1000 mg/day) for a duration ranging from 28 days to 4 months, showed a dose-dependent anti-inflammatory effect and upregulated some mitochondrial genes, markers of autophagy, and fatty acid oxidation. It did not affect mitochondrial maximal adenosine triphosphate production, biogenesis, dynamics, or gut microbiota composition. UA increased muscle strength and endurance, however, had no effect on anthropometrics, cardiovascular outcomes, and physical function. Unrelated adverse events were mild or moderate. Further research across more physiological systems and longer intervention periods is required.

KW - Geroprotectors

KW - Healthy aging

KW - Longevity

KW - Urolithin A

UR - http://www.scopus.com/inward/record.url?scp=85198525627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85198525627&partnerID=8YFLogxK

U2 - 10.1016/j.arr.2024.102406

DO - 10.1016/j.arr.2024.102406

M3 - Review article

C2 - 39002645

AN - SCOPUS:85198525627

SN - 1568-1637

VL - 100

SP - 1

EP - 8

JO - Ageing Research Reviews

JF - Ageing Research Reviews

M1 - 102406

ER -

Targeting aging with urolithin A in humans: A systematic review

Abstract

Bibliographical note

Funding

Keywords

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this